USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 2, 2021 | Sep 2021 | $-0.28 | $-0.34 | $-0.25 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 2, 2021 | Sep 2021 | $1.77M | $1.82M | $1.45M |
Aclaris Therapeutics, Inc's next earnings date is Tuesday, Nov 2, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $-0.37 | $-0.69 | $-0.21 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $-1.54 | $-1.95 | $-1.27 |
| Dec 2022 | 6 | $-1.46 | $-2.00 | $-1.13 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.37 | $-0.37 | $-0.33 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-1.54 | $-1.54 | $-1.34 |
| Dec 2022 | 0 / 0 | $-1.46 | $-1.46 | $-1.32 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $1.78M | $1.40M | $2.10M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $7.17M | $6.50M | $7.70M |
| Dec 2022 | 6 | $7.60M | $6.50M | $8.90M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 2, 2021 | Sep 2021 | $-0.28 | - | - |
| Aug 5, 2021 | Jun 2021 | $-0.28 | $-0.34 | -21.43% |
| May 7, 2021 | Mar 2021 | $-0.28 | $-0.57 | -103.57% |
| Feb 25, 2021 | Dec 2020 | $-0.26 | $-0.30 | -15.38% |
| Nov 4, 2020 | Sep 2020 | $-0.31 | $-0.25 | 18.03% |
| Aug 7, 2020 | Jun 2020 | $-0.36 | $-0.28 | 21.13% |
| May 7, 2020 | Mar 2020 | $-0.38 | $-0.37 | 1.33% |
| Feb 25, 2020 | Dec 2019 | $-0.39 | $-0.45 | -16.37% |
| Nov 7, 2019 | Sep 2019 | $-0.69 | $-1.34 | -94.20% |
| Aug 8, 2019 | Jun 2019 | $-0.75 | $-1.21 | -62.20% |
| May 8, 2019 | Mar 2019 | $-0.80 | $-0.91 | -13.40% |
| Mar 18, 2019 | Dec 2018 | $-0.98 | $-0.99 | -0.68% |
| Nov 6, 2018 | Sep 2018 | $-1.33 | $-1.06 | 20.10% |
| Aug 3, 2018 | Jun 2018 | $-1.09 | $-1.01 | 7.62% |
| May 8, 2018 | Mar 2018 | $-1.00 | $-0.98 | 2.32% |
| Mar 12, 2018 | Dec 2017 | $-0.88 | $-0.74 | 15.91% |
| Nov 7, 2017 | Sep 2017 | $-0.87 | $-0.63 | 27.59% |
| Aug 8, 2017 | Jun 2017 | $-0.73 | $-0.56 | 23.29% |
| May 9, 2017 | Mar 2017 | $-0.59 | $-0.48 | 18.64% |
| Mar 15, 2017 | Dec 2016 | $-0.64 | $-0.49 | 22.83% |
| Nov 3, 2016 | Sep 2016 | $-0.67 | $-0.50 | 25.65% |
| Aug 11, 2016 | Jun 2016 | $-0.65 | $-0.62 | 4.13% |
| May 11, 2016 | Mar 2016 | $-0.50 | $-0.65 | -30.00% |
| Mar 23, 2016 | Dec 2015 | $-0.45 | $-0.28 | 37.78% |
| Oct 13, 2015 | Sep 2015 | $-2.84 | $-5.11 | -79.93% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 25, 2021 | Dec 2020 | $-1.16 | $-1.20 | - |
| Feb 25, 2020 | Dec 2019 | $-4.70 | $-3.91 | - |
| Mar 18, 2019 | Dec 2018 | $-4.02 | $-4.04 | - |
| Mar 12, 2018 | Dec 2017 | $-2.57 | $-2.41 | - |
| Mar 15, 2017 | Dec 2016 | - | $-2.26 | - |
| Mar 23, 2016 | Dec 2015 | - | $-5.39 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 2, 2021 | Sep 2021 | $1.77M | - | - |
| Aug 5, 2021 | Jun 2021 | $1.75M | $1.82M | 1.04% |
| May 7, 2021 | Mar 2021 | $1.48M | $1.78M | 1.20% |
| Feb 25, 2021 | Dec 2020 | $1.39M | $1.58M | 1.14% |
| Nov 4, 2020 | Sep 2020 | $1.47M | $1.45M | 0.99% |
| Aug 7, 2020 | Jun 2020 | $1.23M | $2.05M | 1.66% |
| May 7, 2020 | Mar 2020 | $1.13M | $1.41M | 1.25% |
| Feb 25, 2020 | Dec 2019 | $3.47M | $1.09M | 0.32% |
| Nov 7, 2019 | Sep 2019 | $5.82M | $983.00K | 0.17% |
| Aug 8, 2019 | Jun 2019 | $5.55M | $5.87M | 1.06% |
| May 8, 2019 | Mar 2019 | $5.12M | $5.04M | 0.98% |
| Mar 18, 2019 | Dec 2018 | $3.46M | $3.67M | 1.06% |
| Nov 6, 2018 | Sep 2018 | $1.75M | $1.63M | 0.93% |
| Aug 3, 2018 | Jun 2018 | $3.68M | $3.68M | 1.00% |
| May 8, 2018 | Mar 2018 | $1.00M | $1.12M | 1.12% |
| Mar 12, 2018 | Dec 2017 | $520.00K | $999.00K | 1.92% |
| Nov 7, 2017 | Sep 2017 | $880.00K | $684.00K | 0.78% |
| Aug 8, 2017 | Jun 2017 | $0.00 | $0.00 | - |
| May 9, 2017 | Mar 2017 | - | $0.00 | - |
| Mar 15, 2017 | Dec 2016 | - | $0.00 | - |
| Nov 3, 2016 | Sep 2016 | - | $0.00 | - |
| Aug 11, 2016 | Jun 2016 | - | $0.00 | - |
| May 11, 2016 | Mar 2016 | - | $0.00 | - |
| Mar 23, 2016 | Dec 2015 | - | $0.00 | - |
| Oct 13, 2015 | Sep 2015 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 25, 2021 | Dec 2020 | $6.29M | $6.48M | 3.05% |
| Feb 25, 2020 | Dec 2019 | $17.58M | $4.23M | -75.96% |
| Mar 18, 2019 | Dec 2018 | $9.87M | $10.09M | 2.24% |
| Mar 12, 2018 | Dec 2017 | $1.01M | $1.68M | 66.63% |
| Mar 15, 2017 | Dec 2016 | - | $0.00 | - |
| Mar 23, 2016 | Dec 2015 | - | $0.00 | - |
ACRS's next earnings date is Tuesday, Nov 2, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 6 analysts, the average EPS estimation for Aclaris Therapeutics, Inc's next quarterly earnings is $-0.28, with a low EPS estimation of $-0.35, and a high estimation of $-0.20.
Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $-0.28, the last 2 month trend is $-0.28, and the 3 month trend is $-0.29.
Based on 6 analysts, the average revenue estimation is $1.77M, with a low revenue estimation of $1.50M, and a high estimation of $2.00M.
Aclaris Therapeutics, Inc's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.
ACRS's earnings per share (EPS) was $-0.34, missing the consensus analysts forecast of $-0.28 by -21.43%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -40.35%, and lower than the same period a year before (Jun 2020) by 21.43%.
Revenues were $1.82M, better than the forecast of $1.75M by 4.23%, up by 2.64% from the previous quarter , and down by -10.85% from the same period last year.
The company reported a net income of $-18.16M.Free cash flow for the quarter was $-12.27M , compared to $-12.23M last quarter and $-10.84M a year before.
ACRS ended the quarter with $11.38M in total debt, an increase of 0.54% compared to the previous quarter, and an increase of 1.74% compared to the same quarter a year before.
Aclaris Therapeutics, Inc's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.
ACRS's earnings per share (EPS) was $-1.20, missing the consensus analysts forecast of $-1.16 by 3.45% , and higher than the previous year's EPS (Dec 2019) by -69.31%.
Revenues were $6.48M, better than the forecast of $6.29M by 3.05%, and up by 53.35% from previous year's revenue.
The company reported a net income of $-51.02M.
Aclaris Therapeutics, Inc reported a free cash flow of $-39.09M for its fiscal year, compared to $-98.06M a year ago.
The company ended the fiscal year with $11.26M in total debt, an increase of 1667.03% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
